Intuitive Surgical Inc

Intuitive Surgical manufactures the da Vinci Surgical System, a robotic platform that enables surgeons to perform complex operations through small incisions, reducing patient recovery time [Intuitive.com]. The company also produces the Ion endoluminal system for minimally invasive lung biopsies and provides a full suite of instruments, training, and 24/7 technical support to hospitals [Intuitive.com]. Revenue comes from three streams: selling capital equipment (the robots), selling disposable instruments used during each procedure, and ongoing service contracts [Intuitive.com].

Intuitive Surgical is the dominant maker of robotic surgery systems—primarily the da Vinci platform—that help doctors perform minimally invasive procedures [Intuitive.com]. The stock has fallen 20% year-to-date despite strong underlying business momentum, with procedure volumes up 16% and the new da Vinci 5 system showing higher utilization than prior generations [Yahoo Finance]. The company reported $2.77 billion in Q1 revenue, beating analyst expectations, and continues to expand its installed base at 12% annually [Yahoo Finance].

Financially excellent with strong margins, negative net debt, and high returns on capital [Yahoo Finance].